A Device Just Restored Reading Vision to Blind Patients. Americans Will Wait Years for It.

The gap is wider than the celebratory coverage suggests, and the reasons are specific.

What the device actually does

Age-related macular degeneration destroys the photoreceptors at the center of the retina, the ones responsible for reading and recognizing faces, and its advanced form, geographic atrophy, leaves a blind spot in the middle of vision that nothing has been able to repair. It affects more than five million people worldwide, and until now the treatments only slowed the damage. None restored what was lost.

PRIMA takes a genuinely different approach. A 2mm photovoltaic chip is implanted under the retina, in the atrophied area, and acts like a miniature solar panel. Special glasses project near-infrared light onto the chip, which converts it into electrical signals that stimulate the surviving retinal neurons, bypassing the dead photoreceptors entirely. A zoom feature lets patients magnify text. The light-powered, wireless design is what distinguishes it from earlier retinal prosthetics that largely disappointed.

The results, published in the New England Journal of Medicine, are what earned the attention. In a 38-patient trial across 17 sites in five countries, 84% of patients regained the ability to read letters, numbers, and words, with a mean improvement of 25.5 letters, more than five lines on a standard eye chart, and 80% achieved significant acuity gains at 12 months. An NEJM editorial called it the first treatment to restore vision in these patients. That framing, from that journal, is not marketing.

Why "approved in Europe" and "available in America" are years apart

Here is where the enthusiasm needs a clear-eyed qualifier. The European launch does not translate into US availability on anything like the same timeline, and three separate bottlenecks explain the delay.

The first is regulatory, and the pathway itself is telling. In the US, PRIMA holds FDA Breakthrough Device designation, granted in 2023, and the company requested Humanitarian Use Device designation this spring. That second detail carries information most readers would miss. Humanitarian Use Device is a pathway reserved for devices treating fewer than 8,000 US patients a year, and a company pursuing it is signaling that the initial approved population will be narrow, not the full five million with macular degeneration. It is a real approval route, and it is a deliberately small door.

The second is manufacturing. The company itself has said it is completing manufacturing scale-up to ensure supply chain readiness. Implanting a 2mm photovoltaic array under the retina is not a device you mass-produce quickly, and even after approval, the number of implants that can actually be made and placed in the first years is limited by production and by the supply of surgeons trained to do a delicate subretinal operation.

The third is the one that will decide who actually benefits: reimbursement. Even in Europe, the company noted that country-specific reimbursement applications are underway, which is the real gate. Approval means a device is legal to sell. Reimbursement means someone other than the patient pays for it, and for an implant-plus-surgery-plus-glasses system, the out-of-pocket cost without insurance coverage would be prohibitive for almost everyone. In the US, that means a coverage determination from Medicare, whose beneficiaries are exactly the elderly population that gets macular degeneration. Until Medicare decides to pay, FDA approval is a permission slip most patients cannot use.

The access order is backwards from the need

There is an uncomfortable pattern worth naming, and it is not specific to this company. Breakthrough medical devices tend to reach the wealthy, the well-insured, and patients near major academic medical centers first, and everyone else later, if at all.

Consider what getting PRIMA will require in the early years: proximity to one of a small number of centers with a surgeon trained in the implantation, the ability to navigate a narrow approved indication, and either insurance coverage or the means to pay out of pocket while coverage is still being negotiated. Each of those filters selects for advantage. The patient in a rural area, on Medicaid, far from an academic eye center, is last in every one of those lines despite having the same disease.

This is not a criticism of the device or an argument against celebrating it. It is a reminder that a scientific breakthrough and equitable access to it are two different achievements, and the second usually lags the first by years and sometimes never fully arrives. The NEJM results describe what is medically possible. Who actually gets it is decided by regulatory scope, manufacturing capacity, surgical training, and insurance, and none of those move at the speed of the science.

What is genuinely worth being hopeful about

None of the above diminishes the achievement, and it would be wrong to end on only the caveats.

For the field, PRIMA is proof that the photovoltaic subretinal approach works in humans, which matters beyond this one product. The company is already exploring the same technology for Stargardt disease and retinitis pigmentosa, other conditions that destroy photoreceptors, and is developing next-generation implants aimed at higher resolution and a wider field of view. A first-generation device that restores the ability to read is a floor, not a ceiling, and the trajectory of this kind of technology is usually toward better and cheaper once the core approach is validated.

And the underlying demonstration, that you can bypass dead photoreceptors with a light-powered chip and the brain will make usable vision from the signal, is a genuine milestone in restoring a sense that was considered permanently lost. That is worth the attention it is getting.

The honest full picture is both halves at once. A real breakthrough happened, and it will reach Americans slowly, through a narrow initial indication, limited manufacturing, a short supply of trained surgeons, and an unresolved reimbursement question, with the people who most need it and can least afford it likely waiting longest. Holding both of those together is not pessimism. It is the difference between what medicine can now do and what patients can actually get, and that difference is the story the approval headline leaves out.

Further reading

• Science Corporation's July 22 announcement, on the trial results and reimbursement applications
• Science Corporation, on the device mechanism and subretinal design
• Retinal Physician, on FDA discussions and future indications